Zacks Research Issues Negative Outlook for Hologic Earnings

Hologic, Inc. (NASDAQ:HOLX) – Zacks Research decreased their Q4 2025 earnings per share (EPS) estimates for shares of Hologic in a research note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $1.12 per share for the quarter, down from their prior forecast of $1.13. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s FY2027 earnings at $4.97 EPS.

Several other equities research analysts also recently weighed in on HOLX. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Citigroup decreased their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Hologic currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Up 0.7 %

Shares of NASDAQ:HOLX opened at $61.89 on Monday. Hologic has a 1-year low of $60.34 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market cap of $13.89 billion, a P/E ratio of 19.52, a P/E/G ratio of 2.14 and a beta of 0.97. The firm has a fifty day moving average price of $65.89 and a 200 day moving average price of $73.81.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%.

Institutional Investors Weigh In On Hologic

A number of institutional investors and hedge funds have recently modified their holdings of the company. Benson Investment Management Company Inc. purchased a new stake in Hologic during the fourth quarter worth $4,832,000. Principal Financial Group Inc. raised its stake in shares of Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after buying an additional 1,606 shares during the last quarter. Clean Yield Group boosted its position in shares of Hologic by 18.9% in the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after buying an additional 7,266 shares in the last quarter. Janus Henderson Group PLC grew its stake in Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after acquiring an additional 800 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Hologic during the 3rd quarter valued at about $2,350,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.